Common-Size Income Statement
Difficulty: Beginner
Eli Lilly & Co., Common-Size Consolidated Income Statement
| 12 months ended | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | ||||||
| Cost of sales | -26.54% | -26.65% | -25.24% | -25.15% | -21.24% | ||||||
| Gross margin | 73.46% | 73.35% | 74.76% | 74.85% | 78.76% | ||||||
| Research and development | -23.09% | -24.71% | -24.03% | -24.13% | -23.93% | ||||||
| Marketing, selling, and administrative | -28.81% | -30.40% | -32.73% | -33.75% | -30.83% | ||||||
| Acquired in-process research and development | -4.86% | -0.14% | -2.68% | -1.02% | -0.25% | ||||||
| Asset impairment, restructuring, and other special charges | -7.32% | -1.80% | -1.84% | -2.39% | -0.52% | ||||||
| Operating income | 9.38% | 16.30% | 13.47% | 13.56% | 23.24% | ||||||
| Income related to termination of the exenatide collaboration with Amylin | 0.00% | 0.00% | 0.00% | 0.00% | 2.14% | ||||||
| Interest expense | -0.98% | -0.87% | -0.81% | -0.76% | -0.69% | ||||||
| Interest income | 0.73% | 0.51% | 0.44% | 0.62% | 0.52% | ||||||
| Venezuela charge | 0.00% | -0.96% | 0.00% | 0.00% | 0.00% | ||||||
| Debt extinguishment loss | 0.00% | 0.00% | -0.84% | 0.00% | 0.00% | ||||||
| Other income | 0.48% | 0.92% | 1.71% | 1.88% | 0.28% | ||||||
| Other, net, income (expense) | 0.23% | -0.40% | 0.50% | 1.74% | 2.25% | ||||||
| Income before income taxes | 9.61% | 15.90% | 13.98% | 15.30% | 25.48% | ||||||
| Income taxes | -10.50% | -3.00% | -1.91% | -3.11% | -5.21% | ||||||
| Net income (loss) | -0.89% | 12.90% | 12.07% | 12.19% | 20.27% |
Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).
| Item | Description | The company |
|---|---|---|
| Operating income | The net result for the period of deducting operating expenses from operating revenues. | Eli Lilly & Co.'s operating income as a percentage of revenue increased from 2015 to 2016 but then declined significantly from 2016 to 2017. |
| Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Eli Lilly & Co.'s income before income taxes as a percentage of revenue increased from 2015 to 2016 but then declined significantly from 2016 to 2017. |
| Net income (loss) | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Eli Lilly & Co.'s net income (loss) as a percentage of revenue increased from 2015 to 2016 but then declined significantly from 2016 to 2017. |